Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00314327 · ClinicalTrials.gov registry record · Phase 4
Optimizing Response in Psychosis Study
A Phase 4 study, sponsored by Northwell Health.
- Terminated
- Registry status
- Phase 4
- Development phase
- 1
- Enrollment target
NCT00314327 is a Phase 4 study that was terminated before completion, run by Northwell Health. The registered enrollment target is 1 participants.
The verdict
NCT00314327, a Phase 4 study, was terminated before completion, sponsored by Northwell Health.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this project is to evaluate the efficacy of long-acting risperidone for patients with first episode schizophrenia spectrum who did not improve sufficiently with the first antipsychotic medication they tried during their initial treatment trial.
Interventions
- DRUG long-acting injectable risperidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2006-04 |
| Est. Completion | 2013-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00314327
The ClinicalTrials.gov registry entry for NCT00314327 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which long-acting injectable risperidone is the first listed.
NCT00314327 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00314327 about?
NCT00314327 is a clinical study titled "Optimizing Response in Psychosis Study". The purpose of this project is to evaluate the efficacy of long-acting risperidone for patients with first episode schizophrenia spectrum who did not improve sufficiently with the first antipsychotic medication they tried during their initial treatment trial.
What is the current status of trial NCT00314327?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2006-04. Estimated completion is 2013-11.
What interventions are being tested in trial NCT00314327?
The interventions under investigation include: long-acting injectable risperidone (DRUG).
Who is sponsoring clinical trial NCT00314327?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.